Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone +/- Estramustine in Prostate Cancer
NCT00025194Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ixabepilone in prostate cancer (PCa) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximum Tolerated Dose and Proportion of patients achieving >= 50% post-therapy decline in PSA. Started Jul 2001; status: completed.
02
Drugs
ixabepilone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00025194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025194.